U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Carcinoma

MedGen UID:
1651209
•Concept ID:
C4725612
•
Neoplastic Process

Definition

Ovarian carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Tamoxifen in the treatment of recurrent ovarian carcinoma.
Tropé C, Marth C, Kaern J
Eur J Cancer 2000 Sep;36 Suppl 4:S59-61. doi: 10.1016/s0959-8049(00)00228-8. PMID: 11056321
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol 1989 Aug;16(4 Suppl 6):79-82. PMID: 2669140

Recent clinical studies

Etiology

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W, Li Z, Zheng Z, Wu X
Cancer Med 2020 Aug;9(16):5899-5907. Epub 2020 Jul 6 doi: 10.1002/cam4.3282. PMID: 32627959Free PMC Article
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.
Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW
Eur J Gynaecol Oncol 1995;16(6):439-47. PMID: 8536758
Salvage therapy in epithelial ovarian cancer.
Caldas C, Morris LE, McGuire WP 3rd
Obstet Gynecol Clin North Am 1994 Mar;21(1):179-94. PMID: 8015763
Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age.
Cornelison TL, Reed E
Cancer 1993 Jan 15;71(2 Suppl):650-5. doi: 10.1002/cncr.2820710225. PMID: 8420690

Diagnosis

Inflammatory skin metastases from ovarian carcinoma--a case report and review of the literature.
Schonmann R, Altaras M, Biron T, Bernheim J, Fishman A
Gynecol Oncol 2003 Sep;90(3):670-2. doi: 10.1016/s0090-8258(03)00366-4. PMID: 13678744
Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K, Kikuchi Y, Kudoh K, Nagata I
J Cancer Res Clin Oncol 2000 Mar;126(3):168-72. doi: 10.1007/s004320050027. PMID: 10741911
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol 1995 Jun;57(3):278-85. doi: 10.1006/gyno.1995.1143. PMID: 7774830
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575

Therapy

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W, Li Z, Zheng Z, Wu X
Cancer Med 2020 Aug;9(16):5899-5907. Epub 2020 Jul 6 doi: 10.1002/cam4.3282. PMID: 32627959Free PMC Article
Current status of liposomal anthracycline therapy in metastatic breast cancer.
Rivera E
Clin Breast Cancer 2003 Nov;4 Suppl 2:S76-83. doi: 10.3816/cbc.2003.s.019. PMID: 14667278
Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.
Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH
Clin Oncol (R Coll Radiol) 1994;6(1):40-8. doi: 10.1016/s0936-6555(05)80367-x. PMID: 7909688
Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.
Long HJ
Mayo Clin Proc 1994 Apr;69(4):341-5. doi: 10.1016/s0025-6196(12)62219-8. PMID: 7909575
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article

Prognosis

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.
Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW
Eur J Gynaecol Oncol 1995;16(6):439-47. PMID: 8536758
Salvage therapy in epithelial ovarian cancer.
Caldas C, Morris LE, McGuire WP 3rd
Obstet Gynecol Clin North Am 1994 Mar;21(1):179-94. PMID: 8015763
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH
J Clin Oncol 1992 Apr;10(4):647-56. doi: 10.1200/JCO.1992.10.4.647. PMID: 1312588
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR
J Clin Oncol 1984 Dec;2(12):1321-6. doi: 10.1200/JCO.1984.2.12.1321. PMID: 6542584

Clinical prediction guides

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Galligioni E, Arcuri C, Sorio R, Griso C
Ann Oncol 2006 May;17 Suppl 5:v195-8. doi: 10.1093/annonc/mdj980. PMID: 16807455
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP
J Clin Oncol 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. PMID: 11408492
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F
Cancer Chemother Pharmacol 1998;41(5):385-90. doi: 10.1007/s002800050755. PMID: 9523734
Intraperitoneal therapy in the management of ovarian carcinoma.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis JL Jr
Yale J Biol Med 1989 Jul-Aug;62(4):393-403. PMID: 2688324Free PMC Article
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
Markman M, Cleary S, Lucas WE, Howell SB
J Clin Oncol 1985 Jul;3(7):925-31. doi: 10.1200/JCO.1985.3.7.925. PMID: 3894586

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...